Marsh & McLennan CEO Executes 10b5-1 Plan: 21,079 Shares Sold
Rhea-AI Filing Summary
Marsh & McLennan Companies insider transaction by John Q. Doyle. The filing reports that on 09/02/2025 Mr. Doyle exercised 21,079 stock options with an exercise price of $63.09 and immediately sold 21,079 shares at $205.65 per share. The transactions were executed pursuant to a previously adopted Rule 10b5-1 trading plan. After these transactions Mr. Doyle beneficially owned 87,681.0205 shares of MMC directly. The options exercised were originally granted on May 1, 2016 and vested in four equal annual installments beginning May 1, 2017, with full vesting by 2020.
Positive
- None.
Negative
- None.
Insights
TL;DR: Officer exercised vested 2016 options and sold the resulting shares under a pre-existing 10b5-1 plan; impact appears routine.
The report documents a simultaneous exercise-and-sale of 21,079 shares by the President & CEO, executed under an established Rule 10b5-1 plan on 09/02/2025. The exercise price was $63.09 with a sale price of $205.65 per share, and the reporting person retains 87,681.0205 shares post-transaction. From a disclosure and compliance viewpoint, reliance on a 10b5-1 plan and the fact that the options were long-vested (granted 2016, vested by 2020) indicate a routine liquidity event rather than a special issuance or amendment.
TL;DR: Transaction follows governance best practices by using a documented 10b5-1 plan; no new benefit plan grants disclosed.
The Form 4 shows the CEO transacted under a declared trading plan, which provides an affirmative defense under Rule 10b5-1. The filing discloses the original grant date and vesting schedule for the options (May 1, 2016, vested in four installments through 2020), supporting clarity on option maturity. The disclosure is complete for the reported activities and includes an attorney-in-fact signature confirming timely filing.